Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Preclinical Surgical Engraftment and Implementation

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract, titled Preclinical Surgical Engraftment and Implementation, supports prime contractors within the ARPA-H BRAINS program under the Department of Health and Human Services. The primary objective is to perform surgical implementation and proof-of-concept engraftment of precursor tissue in preclinical models to demonstrate in situ tissue replacement. This involves the development of specialized surgical implementation tools and strategies tailored for specific brain regions. The project is categorized under NAICS code 541715 and is slated for performance in Washington. The solicitation was posted on July 2, 2026, with a response deadline of February 26, 2027. The successful contractor will be responsible for delivering a comprehensive proof-of-concept demonstration of surgical engraftment to validate the efficacy of the precursor tissue implementation.

General Info

ARPA-H subcontract for preclinical surgical engraftment and tissue replacement proof-of-concept in Washington.

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Washington, DC, USA

Set-Aside

NONE

Documents

This scope was carved out of ARPA-H-SOL-26-148.

The full solicitation package (3 documents), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Brain Repair of Any Injured Neural Structure (BRAINS)

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Performs surgical implementation and proof-of-concept engraftment of precursor tissue for prime contractors on ARPA-H BRAINS program projects. Develops surgical implementation tools and strategies for specific brain regions and performs surgical engraftment into preclinical models to demonstrate in situ tissue replacement. Delivers proof-of-concept demonstration of surgical engraftment in preclinical models.

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
Federal
Atomically Precise Molecules (APM)
Solicitation # DARPA-PS-26-141
The Atomically Precise Molecules (APM) program, solicitation DARPA-PS-26-141, is a 36-month initiative by the DARPA Multi X Office seeking innovative synthesis techniques for programmable precision polymers (PPPs) and nonlinear optical (NLO) materials. The program aims to develop scalable materials with strictly controlled monomer sequences and compositions, culminating in a prototype NLO material integrated into a government-provided electro-optic modulator capable of achieving greater than 1THz modulation. The effort is structured in two phases, with Phase I lasting 12 months and focusing on synthesis capabilities. Research limited to inorganic materials or incremental improvements to existing state-of-the-art practices is specifically excluded. Awards will be issued as Other Transaction for Prototype Agreements, with payments processed through the Wide Area Workflow system based on a schedule of milestones. Proposals are due by December 18, 2026, via the Broad Agency Announcement Tool and must include technical, management, and pricing volumes. Eligibility is restricted to U.S. organizations, and all performers must comply with CMMC Level 2 self-certification and NIST SP 800-171 standards for safeguarding Controlled Unclassified Information. Evaluation will be based on technical approach, relevance to the DARPA mission, budget realism, and the capability to transition the technology to military or commercial sectors.
Defense Advanced Research Projects Agcy

POSTED

1 day ago

DEADLINE

in about 2 months
View Details

More opportunities from Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

Same awarding agency

NAICS: 541714
New
Federal
ARPA-H Emerging Health Innovators (EHI) Initiative
Solicitation # ARPA-H-SOL-26-150
The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, seeks to identify and engage early-career investigators to develop cutting-edge biomedical, health, and community-engaged research. This opportunity is open to researchers from academic, nonprofit, and industry organizations, provided the Principal Investigator is within eight years of completing their first terminal degree. The initiative covers 16 specific topic areas, including AI in life sciences, brain stimulation, and human tissue platforms. Awards are issued as Other Transaction (OT) agreements, which are not subject to the Federal Acquisition Regulation (FAR). The selection process is a two-step submission involving an initial anonymized Solution Summary and a subsequent Full Proposal for selected candidates. Successful awards have a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a 24-month base period capped at 700,000 dollars and an optional 12-month Director's Award period capped at 350,000 dollars. Payments are structured as fixed payments triggered by the completion of 12 discrete, measurable milestones. Full proposals are evaluated based on technical merit, innovativeness, feasibility, alignment with the ARPA-H mission to accelerate health outcomes, and price reasonableness. Administrative requirements include mandatory registration in SAM.gov and the use of the ARPA-H Solutions site for all submissions. Proposers must adhere to strict formatting templates for technical and management proposals, milestone schedules, and national policy requirements, including disclosures regarding organizational conflicts of interest and research security. Performance is monitored through a formal inspection and acceptance process where the government reviews deliverables within 14 calendar days. The tentative award start date is June 30, 2027, with full proposals due by February 10, 2027.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

6 days ago

DEADLINE

in 4 months
View Details
NAICS: 541715
Federal
Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening
Solicitation # ARPA-H-SOL-26-160
The Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and Supplies (FASTPASS) program, under solicitation ARPA-H-SOL-26-160, is an initiative by the Advanced Research Projects Agency for Health (ARPA-H) to develop a near real-time, non-destructive, AI-enabled screening system. The goal is to identify contamination, adulteration, and quality defects in pharmaceutical products through their packaging at ports of entry and other supply-chain nodes using multi-modal sensing and data fusion. This 54-month program is structured into three 18-month phases, culminating in a fieldable platform with validated training materials and integrated documentation capabilities. This procurement is conducted as a multiple-award Other Transaction (OT) Agreement rather than a standard federal contract, meaning it is governed by specific OT articles instead of the Federal Acquisition Regulation. Awards are based on the most advantageous proposals, with primary evaluation factors including innovation, soundness, execution planning, risk management, and team expertise. Payments are fixed and triggered by the successful completion of milestones, managed through the Payment Management System. Proposers must be registered in SAM.gov and provide detailed technical and cost proposals, including a milestone payment schedule and research security disclosures. Amendment 01 specifically updated the cost proposal narrative model and workbook to correct typographical errors and rename appendices.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

in 13 days
View Details
NAICS: 541714
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

28 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
Federal
UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)
Solicitation # ARPA-H-SOL-26-162
The Advanced Research Projects Agency for Health (ARPA-H) is seeking innovative solutions through the UNifying Imaging with QUantum Entanglement (UNIQUE) program, solicitation number ARPA-H-SOL-26-162. This 18-month, two-phase initiative aims to develop a new biomedical imaging paradigm by integrating anatomical, functional, and molecular data using quantum-derived observables and entangled 511 keV photon pairs. The scope is divided into two technical areas: the Imaging Core, which focuses on physical systems for generating and measuring quantum observables, and the Computational Foundation, which focuses on AI-driven reconstruction and multimodal data fusion. ARPA-H anticipates awarding multiple Other Transaction Agreements to eligible universities, non-profit organizations, and businesses. The submission process is two-staged, requiring Solution Summaries by late October 2026 and Full Proposals by December 15, 2026. Full proposals must consist of three volumes covering technical and management plans, cost proposals, and administrative requirements. Evaluation is based on technical innovation and feasibility, proposer expertise, potential to transform biomedicine, and cost reasonableness. Notably, for-profit organizations that are not small businesses under NAICS 541714 are required to provide a meaningful cost share. All participants must adhere to strict HHS regulations regarding human stem cell research and prohibitions on dangerous gain-of-function research and funding for foreign entities in countries of concern.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in about 2 months
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS